Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States

Charles McCrea,Sukhvinder Johal,Shuo Yang,Justin Doan

Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States

2018

Charles McCrea
Sukhvinder Johal
Shuo Yang
Justin Doan

Background We evaluated the cost-effectiveness of nivolumab versus everolimus in patients with advanced renal cell carcinoma (RCC) from a US payer perspective.

Keywords:

Nivolumab
Everolimus
Renal cell carcinoma
Cancer research
Medicine
Oncology
Internal medicine
cost effectiveness
in patient
Progressive disease
Survival analysis
sensitivity analyses

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations